slit: dealing with trouble, doing it right. giovanni b pajno md professor of pediatrics department...
Post on 01-Jan-2016
216 Views
Preview:
TRANSCRIPT
SLIT: dealing with trouble, doing it right.
Giovanni B Pajno MDProfessor of Pediatrics
Department of Pediatrics – Allergy Unit
University of Messina Italy
Allergy School An Insight into Allergy and
Allergen Immunotherapy 11 – 13 September 2014
Athens, Greece
FDA Committee Votes to Approve SLIT TreatmentsLast month, the Allergenic Products Advisory Committee (APAC) of the Food and Drug Administration (FDA) met and voted that the available safety and efficacy data support approval of two sublingual allergy immunotherapy (AIT) products.One is a grass pollen AIT tablet developed by Stallergenes and the other is Merck’s grass pollen AIT tablet. The APAC voted 9-1 regarding approval of the Stallergenes tablet and 9-0 regarding the Merck tablet. The FDA will need to give final approval, but it usually follows the advice of its advisory committees.AAAAI President Linda Cox, MD, FAAAAI, said in an email to members:“There are no FDA-approved forms of sublingual AIT currently available here in the United States, so these products would be the first licensed therapies of their kind. It’s worth noting that the committee felt very strongly about including language in the prescribing instructions for both products that recommended the patient has autoinjectable epinephrine in the event of a severe allergic reaction."
Dr. Cox also discusses the news in this month's President's Message.More information, including a webcast of the meetings, is available from the FDA website
1. Early intervention
2. Long lasting effect
3. Adherence
SLIT
1. Early intervention
2. Long lasting effect
3. Adherence
SLIT
Increasing post-natal age
Birth SLITHampering
the progression and worsening of IgE
mediated disorders
Allergens Exposure
Food AllergensInhalant Allergens
TH2 polarized Immunity
Persistent WheezeAtopic Dermatitis
Hay FeverFood Allergy
Persistent Allergic Diseases
J Allergy Clin Immunol 2007;119:796-801.
G.B. Pajno
(Di Rienzo V et al. Clin Exp Allergy 2003;33:206-210)
Figure 1. Percentage of children in the immunotherapy and control groups who developed asthma after 3 years, in the 3 available trials. In the study by Marogna et al,37 the development of persistent asthma was assessed
Specific immunotherapy: beyond the clinical scoresPassalacqua GAnnals of Allergy 2011;107:401-406
1. Early intervention
2. Long lasting effect
3. Adherence
SLIT
- SLIT
1. Early intervention
2. Long lasting effect
3. Adherence
SLIT
J Allergy Clin Immunol. 2005;116:1380-1
J Allergy Clin Immunol. 2005;116:1380-1
Allergen immunotherapy practice parameter , JACI 2010
Discontinuation 52% three y. old
18% four y. "
13% five y. "
CONCLUSION
Table 1. Comparison between SCIT and SLIT: Similarities and Diversities
Shared Effective for both allergic rhino-conjunctivitis and allergic asthma.
Disease modifying.- Possible prevention of new sensitivities in patients (mostly children) who are monosensitized to house dust mite.-Persistence of benefit for several years after discontinuation.-Possible prevention of allergic asthma?
Immunological mechanisms of action.
Differing Severity of systemic reactions (favours SLIT)
Effectiveness of multiple allergen extracts (favours SCIT)
Adherence to therapy (favours SCIT)
Treatment of young allergic children (favours SLIT)
Exp Review Clin Immunol in press
Pajno G et al.
top related